Expression of CRABP1, GRP, and RERG mRNA in clinically non-functioning and functioning pituitary adenomas
暂无分享,去创建一个
D. Giannella‐Neto | M. Côrrea-Giannella | M. Bronstein | T. Chile | M. L. Corrêa-Giannella | M. A. H. Z. Fortes | M. D. Bronstein | M. B. Cunha-Neto | D. Giannella-Neto | R. R. Giorgi | R. Giorgi | T. Chile | M. Fortes
[1] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[2] S. Schulz,et al. Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies , 2006, Virchows Archiv.
[3] S Rozen,et al. Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.
[4] C. Denef,et al. Evidence for the presence of gastrin-releasing peptide immunoreactivity in rat anterior pituitary corticotrophs and lactotrophs, AtT20 cells, and GH3 cells: failure to demonstrate participation in local control of hormone release. , 1991, Endocrinology.
[5] A. de la Chapelle,et al. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma , 2003, International journal of cancer.
[6] U. Knigge,et al. Gastrin-releasing peptide stimulation of corticotropin secretion in male rats. , 1992, Endocrinology.
[7] G. Stalla,et al. Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas , 2009, Reviews in Endocrine and Metabolic Disorders.
[8] L. Gudas,et al. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells. , 1992, The Journal of biological chemistry.
[9] D. Chung,et al. Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma , 2008, Proceedings of the National Academy of Sciences.
[10] C. Denef,et al. Expression of the genes encoding bombesin-related peptides and their receptors in anterior pituitary tissue , 1993, Molecular and Cellular Endocrinology.
[11] J. Mulshine,et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. , 1997, Chest.
[12] P. Beck‐Peccoz,et al. Effect of 9-cis Retinoic Acid on Dopamine D2 Receptor Expression in Pituitary Adenoma Cells , 2008, Experimental biology and medicine.
[13] L. Gudas,et al. Overexpression of the cellular retinoic acid binding protein-I (CRABP- I) results in a reduction in differentiation-specific gene expression in F9 teratocarcinoma cells , 1991, The Journal of cell biology.
[14] R. Jensen,et al. Mammalian Bombesin Receptors : Nomenclature , Distribution , Pharmacology , Signaling , and Functions in Normal and Disease States , 2008 .
[15] M. Donovan,et al. The cellular retinoic acid binding proteins , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[16] B. Swearingen,et al. Differential Expression of Estrogen Receptor-β (ERβ) in Human Pituitary Tumors: Functional Interactions with ERα and a Tumor-Specific Splice Variant1 , 1998 .
[17] E. Uhl,et al. Retinoic acid prevents experimental Cushing syndrome. , 2001, The Journal of clinical investigation.
[18] G. Norstedt,et al. Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium. , 2002, Molecular human reproduction.
[19] Y. Byun,et al. The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma. , 2004, Metabolism: clinical and experimental.
[20] D. Chung,et al. Gastrin-Releasing Peptide Is a Growth Factor for Human Neuroblastomas , 2002, Annals of surgery.
[21] J. Inazawa,et al. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma , 2007, Oncogene.
[22] M. Loda,et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.
[23] David Botstein,et al. RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* , 2001, The Journal of Biological Chemistry.
[24] S. Wiseman,et al. TIMP1 and SERPIN‐A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma , 2004, Head & neck.
[25] P. Viganò,et al. Accumulation of retinoid X receptor-alpha in uterine leiomyomas is associated with a delayed ligand-dependent proteasome-mediated degradation and an alteration of its transcriptional activity. , 2007, Molecular endocrinology.
[26] Xianquan Zhan,et al. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. , 2005, Cancer research.
[27] J. Burdman,et al. Estrogen Receptors in Human Pituitary Tumors , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[28] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[29] J. Herman,et al. CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Szepesházi,et al. Targeted cytotoxic analogue of bombesin/ gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice , 1999, British Journal of Cancer.
[31] D. Giannella‐Neto,et al. Metallothionein Isoform 3 Gene Is Differentially Expressed in Corticotropin-Producing Pituitary Adenomas , 2006, Neuroendocrinology.
[32] R. Ward,et al. Colorectal cancer: a model for epigenetic tumorigenesis , 2006, Gut.
[33] Xuanchun Wang,et al. Gene expression profiling in human null cell pituitary adenoma tissue , 2007, Pituitary.
[34] Z. Fang,et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. , 2007, The American journal of pathology.
[35] K. Horiguchi,et al. Reduction of retinaldehyde dehydrogenase 1 expression and production in estrogen-induced prolactinoma of rat , 2008, Medical Molecular Morphology.
[36] R. Lothe,et al. ADAMTS1, CRABP1, and NR3C1 Identified as Epigenetically Deregulated Genes in Colorectal Tumorigenesis , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[37] Qinghua Wu,et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets , 2007, Molecular Cancer.
[38] S. Czirják,et al. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. , 2005, European journal of endocrinology.
[39] D. Brat,et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. , 2001, The Journal of clinical endocrinology and metabolism.
[40] W. L. Dees,et al. Evidence for a physiological role of hypothalamic gastrin-releasing peptide to suppress growth hormone and prolactin release in the rat. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Geffers,et al. Cellular Retinoic Acid Binding Protein I: Expression and Functional Influence in Renal Cell Carcinoma , 2005, Tumor Biology.
[42] Wook Kim,et al. Expression of the RERG Gene is Gender-Dependent in Hepatocellular Carcinoma and Regulated by Histone Deacetyltransferases , 2006, Journal of Korean medical science.
[43] S. Melmed,et al. Diagnosis and management of nonfunctioning pituitary tumors. , 1996, Annual review of medicine.
[44] F. Holsboer,et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. , 2006, Endocrinology.